Berlion M - Search Results

1

[Quantitative cytological study of the activity of a new resistance modulator, S 9788, on human leukemic cells using multiparametric image analysis].

Oum'Hamed Z, Berlion M, Millot-Broglio C, Dufer J, Joly P, Bizzari JP, Desplaces A. Oum'Hamed Z, et al. Among authors: berlion m. Bull Cancer. 1994 Mar;81(3):203-11. Bull Cancer. 1994. PMID: 7894128 French.

2

In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model.

Cros S, Guilbaud N, Berlion M, Dunn T, Regnier G, Dhainaut A, Atassi G, Bizzari JP. Cros S, et al. Among authors: berlion m. Cancer Chemother Pharmacol. 1992;30(6):491-4. doi: 10.1007/BF00685604. Cancer Chemother Pharmacol. 1992. PMID: 1394807

3

[Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].

Fischel JL, Formento P, Berlion M, Berille J, Gioanni J, Bizzari JP, Milano G. Fischel JL, et al. Among authors: berlion m. Bull Cancer. 1992;79(1):81-90. Bull Cancer. 1992. PMID: 1520955 French.

4

Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.

Pierré A, Kraus-Berthier L, Atassi G, Cros S, Poupon MF, Lavielle G, Berlion M, Bizzari JP. Pierré A, et al. Among authors: berlion m. Cancer Res. 1991 May 1;51(9):2312-8. Cancer Res. 1991. PMID: 2015595

5

[Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].

Fischel JL, Barbé V, Berlion M, Formento P, Berrile J, Bizzari JP, Milano G. Fischel JL, et al. Among authors: berlion m. Bull Cancer. 1994 Jul;81(7):599-604. Bull Cancer. 1994. PMID: 7742602 French.

6

In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.

Soudon J, Berlion M, Lucas C, Haddad P, Bizzari JP, Calvo F. Soudon J, et al. Among authors: berlion m. Cancer Chemother Pharmacol. 1995;36(3):195-203. doi: 10.1007/BF00685846. Cancer Chemother Pharmacol. 1995. PMID: 7781138 Clinical Trial.

7

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

Julia AM, Roché H, Berlion M, Lucas C, Milano G, Robert J, Bizzari JP, Canal P. Julia AM, et al. Among authors: berlion m. Br J Cancer. 1994 May;69(5):868-74. doi: 10.1038/bjc.1994.168. Br J Cancer. 1994. PMID: 8180016 Free PMC article.

8

Differential in vitro action of S-12363, a new vinblastine derivative, and of its epimer on microtubule proteins.

Wright M, Garès M, Verdier-Pinard P, Moisand A, Berlion M, Legrand JJ, Bizzari JP. Wright M, et al. Among authors: berlion m. Cancer Chemother Pharmacol. 1991;28(6):434-40. doi: 10.1007/BF00685819. Cancer Chemother Pharmacol. 1991. PMID: 1934248

9

Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.

Berlion M, Arvelo F, Leonce S, Bourgeois Y, Rigaudy P, Bizzari JP, Poupon MF. Berlion M, et al. In Vivo. 1993 Sep-Oct;7(5):399-405. In Vivo. 1993. PMID: 7906553

10

Evaluation of the time-schedule dependency for the cytotoxic activity of the new vinca alkaloid derivative, S 12363 (vinfosiltine).

Fischel JL, Berlion M, Formento P, Bizzari JP, Milano G. Fischel JL, et al. Among authors: berlion m. Eur J Cancer. 1993;29A(13):1890-4. doi: 10.1016/0959-8049(93)90544-p. Eur J Cancer. 1993. PMID: 8260248

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters